RECRUITING

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Official Title

The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer

Quick Facts

Study Start:2022-08-31
Study Completion:2029-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05502523

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
  2. * Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease
  1. * Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
  2. * Preoperative chemotherapy, immunotherapy, or radiation therapy
  3. * Receipt of perioperative blood transfusion

Contacts and Locations

Study Contact

Tyler Grenda, MD
CONTACT
215-955-5562
Tyler.grenda@jefferson.edu

Principal Investigator

Tyler Grenda, MD
PRINCIPAL_INVESTIGATOR
TJU

Study Locations (Sites)

Abington Memorial Hospital
Abington, Pennsylvania, 19001
United States
Jefferson Health Northeast
Philadelphia, Pennsylvania, 19107
United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
United States
Asplundh Cancer Pavilion at Jefferson Health
Willow Grove, Pennsylvania, 19090
United States

Collaborators and Investigators

Sponsor: Thomas Jefferson University

  • Tyler Grenda, MD, PRINCIPAL_INVESTIGATOR, TJU

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-31
Study Completion Date2029-01-01

Study Record Updates

Study Start Date2022-08-31
Study Completion Date2029-01-01

Terms related to this study

Additional Relevant MeSH Terms

  • Lung Non-Small Cell Carcinoma
  • Stage I Lung Cancer AJCC v8
  • Stage II Lung Cancer AJCC v8
  • Stage III Lung Cancer AJCC v8